Drug Profile
Research programme: lipid metabolism therapies - Astria Therapeutics
Alternative Names: CAT 2000; CAT 3000Latest Information Update: 09 Sep 2021
Price :
$50
*
At a glance
- Originator Catabasis Pharmaceuticals
- Developer Astria Therapeutics
- Class Eicosanoids; Nicotinic acids; Omega 3 fatty acids; Small molecules
- Mechanism of Action Arachidonic acid inhibitors; Cyclooxygenase inhibitors; Inflammation mediator inhibitors; Platelet aggregation inhibitors; Sterol regulatory element binding protein modulators; Triglyceride modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dyslipidaemias; Hypertriglyceridaemia
Most Recent Events
- 08 Sep 2021 Catabasis Pharmaceuticals is now called Astria Therapeutics
- 28 Aug 2018 No recent reports of development identified for preclinical development in Dyslipidaemias in USA
- 28 Aug 2018 No recent reports of development identified for preclinical development in Hypertriglyceridaemia in USA